Back to top

MTN-039 is a Phase I study evaluating whether a fast-dissolving insert containing the antiretroviral drugs tenofovir alafenamide (TAF) and elvitegravir (EVG) is safe to use in the rectum. The study will include approximately 20 HIV-uninfected individuals at two sites in the United States.  It will help determine whether further testing on the safety and acceptability of a TAF/EVG rectal insert for preventing HIV from anal sex can be conducted in a larger population. Results are anticipated by late 2020.


MTN-039 Backgrounder